Moderna and Merck Say mRNA Melanoma Therapy Met Phase 3 Endpoints; Moderna Stock Closes Up 177%
The companies reported topline results from a 1,137-patient trial without releasing the size of the benefit, and Moderna's shares closed at $174.38 on August 19, 2026.
A Trial Result With No Numbers Attached Sent Moderna Up 177% in a Day
Merck and Moderna said on August 19, 2026, that their experimental melanoma therapy worked. That's the whole announcement, in one sentence: the drug hit its main goal in a large trial[1][2]. What they didn't say is how well it worked.
There's no hazard ratio in the release — the number that tells doctors how much a treatment lowers a patient's risk compared to not getting it. There's no absolute difference between the two patient groups. And survival data, meaning whether patients actually live longer, isn't ready yet[1][11]. Investors didn't wait for those numbers. Moderna's stock closed at $174.38, up 176.97% in a single session, on trading volume nearly 20 times its normal average[5]. That reaction, built on a result nobody outside the two companies has actually seen in detail, is the story underneath the story.
What the Trial Actually Tested
The therapy is called intismeran autogene. It's made individually for each patient, from a sample of that patient's own tumor[7]. The idea is that a tumor carries mutations that produce proteins healthy cells don't have. The mRNA shot is built to teach the immune system to recognize those specific proteins and attack them.
It's given alongside Merck's Keytruda, a drug that works by releasing a brake the immune system puts on itself, so it can go after cancer more aggressively. The trial, called INTerpath-001, enrolled 1,137 patients with stage IIB through IV melanoma who'd already had their tumors surgically removed[3]. Patients were split two to one, with more getting the combination than Keytruda alone.
The companies say the combination beat Keytruda alone on two measures: recurrence-free survival, meaning how long patients went before their cancer came back, and distant metastasis-free survival, meaning how long before the cancer spread to new parts of the body[1]. Both are legitimate, meaningful outcomes for a patient who just had a tumor removed and is waiting to find out if it's really gone. But neither one is the same as living longer, which is a separate question the current data can't yet answer[1][11].
The Market Priced a Number It Hasn't Seen
Companies aren't required to release full trial data the moment they release a headline result. The routine sequence is: announce that a trial "met its endpoints" first, then present the actual figures later at a medical conference[1][3]. That's legal, and it's standard. It also means, in this case, that the market spent a day pricing a drug based on a claim it can't independently check.
The only real numbers available come from a much smaller earlier study, called Phase 2b. In that trial, the risk of recurrence or death fell 49%, with a hazard ratio of 0.51[11]. That's a meaningful effect if it holds up. But the confidence interval around it ran from 0.294 to 0.887 — a wide range that reflects how much uncertainty comes from testing on a much smaller group of patients. The overall-survival signal in that same study was weaker still, with a confidence interval stretching from 0.165 to 1.345[11]. Because that range crosses 1.0, it's statistically consistent with no effect at all. None of that data is a stand-in for what the new, larger Phase 3 trial actually found. It's simply the last real number the public has.
Moderna's stock move has its own separate logic. The company's shares had fallen for four straight years and sat about 94% below their 2021 pandemic peak[5]. A stock that beaten-down, and that heavily bet against by short sellers, can swing hard on a single piece of news regardless of the underlying number. Short sellers reportedly lost about $5.5 billion on paper in one day, and roughly $7.7 billion so far this year[14]. Moderna's revenue didn't change at all on August 19. Its market value rose by about $44 billion, from roughly $25 billion to about $69 billion[5][14].
Two Companies With Two Different Clocks Running Out
Merck's motivation is patents. Keytruda is one of the best-selling drugs in the world, and its core patents expire later this decade — a cliff worth tens of billions of dollars in future revenue[6]. Pairing it with a personalized therapy that has its own separate patent protection is one way to extend that franchise past the expiration date. Merck's shares closed up 12.6% on the news, a far smaller move than Moderna's, reflecting that Keytruda is already a massive, established product rather than a company waiting on a second act[9].
Moderna's clock is different. Its COVID vaccine revenue has fallen sharply since the pandemic peak, and the company has needed a new product line for years[5]. An oncology win reframes Moderna from a fading pandemic-era company into a broader platform business with more than one working technology[14]. That's a real commercial incentive, and it's also exactly why skeptics say the company had reason to announce a topline win quickly rather than wait months for a full data readout.
A Cut Federal Program and a Trial It Didn't Fund
There's a political layer sitting on top of the market one. In August 2025, the Department of Health and Human Services under Secretary Robert F. Kennedy Jr. canceled about $500 million in mRNA vaccine funding across 22 projects, arguing the mRNA platform carried more risk than benefit for the diseases it was targeting[10]. That came after HHS had already canceled a $766 million Moderna contract that May[16].
Those cuts targeted infectious-disease vaccines — shots given to broad, healthy populations to prevent things like flu or bird flu. This melanoma trial is a different kind of product aimed at a different kind of patient: someone who already has cancer, being treated with a therapy custom-built from their own tumor. HHS's position rests on that distinction — that a personalized cancer treatment carries a different risk calculation than a mass vaccination campaign, and that the department's skepticism was always about the latter[10]. Critics of the cuts read the timing differently. CNN and NBC framed the trial result as a vindication of mRNA technology at the exact moment the administration was pulling federal money from it, and pointed out that this program was funded by two private companies, not by any of the canceled federal contracts[10][13]. Both readings can be true at once: the specific dollars that were cut didn't touch this trial, and the platform those dollars would have supported is the same one that just produced a result this significant.
How the Coverage Split Without Splitting the Facts
Nobody in the mainstream coverage disputed that the trial hit its endpoints. What varied was how much daylight outlets left between "met its endpoints" and "works." STAT led its headline with "Moderna and Merck say," keeping the claim attributed to the companies rather than stated as fact, and led with the missing effect size[3]. Fox's coverage led with "breakthrough" and a 160% stock figure — actually an intraday number, not the 176.97% closing figure most other outlets used — and mentioned the HHS funding cuts only as background context near the end[6].
Al Jazeera's framing left out the U.S. political fight and the stock market entirely, describing the therapy in more finished terms, as a vaccine that "cuts spread," and centering how it's built from a patient's own tumor[7]. Bloomberg described the news as reviving "mRNA hopes," a framing that treats the result partly as a comeback story for the technology's public standing, on top of being a single trial readout[8]. None of these differences change the underlying facts. They change which parts of the story get the emphasis, and how finished the result is made to sound.
What Nobody Can Answer Yet
The one number everyone is arguing about — how much this therapy actually reduces the odds of a melanoma patient's cancer returning — isn't public. Regulators have presumably seen more than the market has, but the full dataset hasn't been presented at a conference or published[1][3]. Whether patients getting this combination will live longer than patients on Keytruda alone remains an open question the current data can't settle[1][11].
There are practical unknowns sitting behind the scientific ones, too. A therapy built individually from each patient's tumor has to be sequenced, designed and manufactured on a clock, for one person at a time — a supply chain problem as much as a science one[3]. Price, insurance coverage, and how many patients could realistically be treated at once haven't been addressed. Melanoma patients who've had their tumors removed still face a real chance of recurrence, which is why delaying that outcome matters to them even before the survival numbers exist[7]. For now, the trial has a headline. The data that would let an outside doctor or investor judge it for themselves is still to come.
Summary
On August 19, 2026, Merck and Moderna said a late-stage trial of their personalized mRNA cancer therapy hit its main goal[1][2]. The therapy, called intismeran autogene, is given with Merck's immunotherapy drug Keytruda. It is made from a sample of each patient's own tumor. The trial enrolled 1,137 patients whose melanoma had been surgically removed[3]. Patients getting the combination went longer without their cancer coming back than patients on Keytruda alone[1]. The companies say this is the first Phase 3 success for an mRNA cancer therapy[2].
Investors reacted hard. Moderna closed at $174.38, up 176.97% in one day[5]. That took the company's market value from roughly $25 billion to about $69 billion — a gain of about $44 billion. Merck closed up 12.6%[9]. Moderna's stock had fallen four years in a row and sat about 94% below its 2021 peak before the news[5].
The main point of genuine dispute is not whether the trial succeeded. It is how much the therapy actually helped. Merck and Moderna released only "topline" results — the statement that the goals were met — without the numbers behind them[1]. They did not give a hazard ratio or an absolute difference. Overall survival, meaning whether patients live longer, is not yet mature[1][11]. Supporters say a win on recurrence in a trial this size is a real turning point for a technology many doubted. Skeptics say a stock cannot triple on a result nobody outside the companies has seen.
There is a political layer too. Health Secretary Robert F. Kennedy Jr. canceled about $500 million in mRNA vaccine contracts across 22 projects in August 2025, arguing the platform carries more risk than benefit[10]. HHS had already canceled a $766 million Moderna contract that May[16]. Those cuts targeted infectious-disease vaccines, not this cancer program. Both sides now cite the melanoma result — one as proof the cuts were misguided, the other as proof private industry can carry the work without federal money.
The Event
On August 19, 2026, Merck and Moderna announced topline results from the Phase 3 INTerpath-001 trial[1][2]. The trial tested intismeran autogene, an individualized mRNA therapy, plus pembrolizumab (Keytruda) against pembrolizumab alone in 1,137 patients with completely resected stage IIB-IV melanoma, randomized 2 to 1[3]. The companies said the combination met the primary endpoint of recurrence-free survival and the key secondary endpoint of distant metastasis-free survival, without disclosing the size of the benefit[1]. Moderna shares closed at $174.38, up 176.97% on volume of 185.1 million shares; Merck closed up 12.6%[5][9].
Undisputed Facts
- Merck and Moderna announced the topline Phase 3 result on August 19, 2026[1][2].
- The trial, INTerpath-001, enrolled 1,137 patients with surgically removed stage IIB-IV melanoma, randomized 2:1[3].
- The companies stated the trial met its primary endpoint of recurrence-free survival and its key secondary endpoint of distant metastasis-free survival[1].
- The announcement did not include a hazard ratio or an absolute difference between the two groups, and the data have not been presented at a medical meeting or published[1][3].
- Overall survival data from the Phase 3 trial are not yet mature[1][11].
- Moderna stock closed August 19 at $174.38, up 176.97%, on 185.1 million shares traded versus a three-month average near 9.6 million[5].
- Merck shares closed up 12.6% the same day[9].
- In August 2025, HHS said it would wind down mRNA vaccine development at BARDA, canceling about $500 million across 22 projects[10].
The Pressure
Strip away the moralizing and blame. What structural realities persist regardless of which narrative wins?
- Merck's patent cliff
- Keytruda is one of the best-selling drugs in the world and its key patents run out later this decade[6]. Merck needs products that extend or replace that revenue. A combination therapy that makes Keytruda work better, and that carries its own patents, is exactly that. This shapes how hard Merck pushes the program regardless of how the final numbers land.
- Moderna's post-COVID revenue hole
- COVID vaccine sales have fallen and the stock declined four years running before this week[5]. The company has to show the mRNA platform does something else. That creates a strong pull toward announcing a win early, in topline form, rather than waiting for a medical meeting.
- Topline disclosure rules
- Public companies must disclose material trial results promptly, but they are not required to release the full dataset at the same time. So the standard sequence — announce that endpoints were met, publish the numbers months later at a conference — is legal and routine. It also means the market prices a result before anyone outside can check it[1][3].
- One drug per patient
- An individualized therapy is manufactured from each person's tumor. That is a supply-chain problem, not just a science problem: sequencing, design, and production per patient, on a clock, before the cancer returns. Cost and capacity will shape access even if the drug is approved[3].
- Political exposure of the mRNA platform
- HHS canceled roughly $500 million in mRNA contracts in August 2025 and a $766 million Moderna contract that May[10][16]. Whatever the cancer data show, federal support for the platform is a live political variable that affects early-stage research funding and hiring[15].
Material realityA trial of 1,137 patients with surgically removed stage IIB-IV melanoma reported that adding a personalized mRNA therapy to Keytruda delayed recurrence more than Keytruda alone[1][3]. That is the whole verified record so far. The size of the benefit is unknown outside the companies and regulators. Whether patients live longer is unknown, because overall survival data are immature[1][11]. Moderna's revenue did not change on August 19; its market value rose about $44 billion, from roughly $25 billion to about $69 billion[5][14]. Melanoma remains the most lethal common skin cancer, and patients whose tumors are removed still face a real risk of return — which is why a recurrence endpoint matters to them even before survival data exist[7]. Nothing about manufacturing capacity, price, or insurance coverage has been settled[3].
Narrative as a weaponThree groups are actively shaping how this reads. Merck and Moderna control the only copy of the data and released the conclusion without the numbers; they want you to believe the milestone is settled and the details are a formality[1][2]. Investors and market media want you to believe the price move is information — that a 176.97% one-day gain reflects what the drug is worth, when it partly reflects a heavily shorted, beaten-down stock repricing all at once[5][14]. And both sides of the mRNA political fight want the trial as a trophy: critics of HHS read it as proof the funding cuts were wrong, while HHS's defenders read it as proof that industry funds the useful work anyway and that a personalized cancer therapy says nothing about mass-vaccination policy[10][15]. The one thing none of them can supply right now is the number everyone is arguing about.
How Each Side Sees It
Each major actor’s view — how it frames things, its underlying incentive, and how it’s materially affected. Tap a side to read it.
Frames it asModerna's case is that mRNA was never only a COVID technology. The same platform that codes a viral protein can code the specific mutations in one person's tumor. That is the whole idea of a "neoantigen" therapy: a tumor's mutations produce proteins that healthy cells do not have, and the shot trains the immune system to hunt exactly those. Moderna argues a randomized Phase 3 win in more than 1,100 patients is the proof the field has waited a decade for, and that it validates a manufacturing system that builds a custom drug per patient[1][2]. On the missing numbers, the company's position is standard practice: topline first, full data at a medical meeting, with regulators seeing everything either way[3].
WhyModerna needed a second act. COVID vaccine revenue has fallen sharply and the stock had declined four straight years, sitting about 94% below its 2021 peak before this news[5]. An oncology franchise changes the company's story from a fading pandemic winner to a platform business[14].
Impact on themMarket value rose from about $25 billion to roughly $69 billion in a single session[5]. That makes raising money far cheaper. Investors betting against the stock — short sellers — were hit with roughly $5.5 billion in paper losses in one day by one estimate, part of about $7.7 billion for the year[14].
Frames it asMerck's argument is about the future of Keytruda. Keytruda releases a brake on the immune system so it can attack tumors, but it works best when the immune system already knows what to attack. Merck's case is that a personalized mRNA therapy supplies the target list, and the two together do what neither does alone[1]. Merck also frames this as expanding the standard of care after surgery, where the goal is stopping cancer from coming back at all[11].
WhyKeytruda's key patents expire later this decade, a revenue cliff worth tens of billions of dollars[6]. Pairing it with a partner drug that is itself patent-protected extends the franchise past that date.
Impact on themShares closed up 12.6% on the announcement[9]. Merck runs the trial program and shares costs and profits with Moderna under their collaboration[2].
Frames it asTheir argument is not that the trial failed. It is that "met its endpoint" is a statistical statement, not a clinical one. A result can clear the bar for statistical significance and still be small. The hazard ratio — the number that says how much the risk of recurrence dropped — has not been released[1]. Nor has overall survival, meaning whether patients actually live longer[11]. They note the reference points come from Phase 2b, a much smaller study, where the risk of recurrence or death fell 49% (hazard ratio 0.51, 95% confidence interval 0.294–0.887) and the overall-survival signal was only a trend (hazard ratio 0.471, 95% confidence interval 0.165–1.345)[11]. A confidence interval that wide crossing 1.0 means the true effect could be large, or could be nothing. Their point: markets priced a number nobody has seen.
WhyProfessional credibility rests on not being wrong twice. Adjuvant cancer trials have a history of recurrence benefits that did not translate into longer life, and reviewers who flag that early are protected if it happens again[3].
Impact on themTheir caution shapes how the eventual full dataset is received, and how payers and regulators treat a therapy that must be manufactured one patient at a time[3].
Frames it asTheir strongest case separates the platform from the use. HHS's stated reason for winding down BARDA's mRNA work was pandemic preparedness: that mRNA vaccines against respiratory viruses underperform as the virus mutates, and that money is better spent on platforms that stay effective across strains[10]. A cancer therapy made from one patient's tumor is a different product with a different risk calculation — the patient already has a life-threatening disease, and the therapy is not given to the healthy public. Critics also point out that this program was funded by two large companies, not by the federal contracts that were canceled, which they read as evidence the cuts did not block the science[10].
WhyKennedy has built a public record on vaccine skepticism and has to reconcile it with a high-profile mRNA success. Drawing a line between mass-vaccination mRNA and personalized cancer mRNA preserves both positions[15].
Impact on themHHS canceled about $500 million across 22 mRNA projects in August 2025, after canceling a $766 million Moderna contract that May[10][16]. Researchers say the indirect effect is on early-stage work and talent, not on this specific late-stage program[15].
Frames it asFor patients, the relevant question is narrow and practical. "Adjuvant" treatment means treatment after the tumor has already been cut out, when scans look clean but cancer may still return. Recurrence-free survival is exactly the thing those patients fear most. Their advocates argue that even without overall-survival data, delaying or preventing a return has real value — fewer relapses, less metastatic disease, fewer second rounds of treatment[7][13]. The counterweight is access: a therapy built individually from each tumor takes weeks to make and is unlikely to be cheap[3].
WhyPatient groups want the therapy reviewed fast and covered by insurance, and they want the full dataset published so doctors can counsel patients honestly[13].
Impact on themIf regulators approve, the therapy could reach patients as soon as next year according to company statements reported at the time[6]. Manufacturing capacity, price, and insurance coverage remain unsettled[3].
Like this article?
The Bias Ledger average rating 3.9
The same story, as framed by outlets across the spectrum, ordered least to most biased. The bias score (1 = straight, 10 = heavily spun) is an AI assessment of that framing — click an outlet to see its track record. The tell is the word choice or omission that reveals the angle.
| Outlet | Vantage | Bias | How they frame it | The tell |
|---|---|---|---|---|
| STAT | U.S. health/science trade press | 2 | "Moderna and Merck say mRNA cancer vaccine succeeded in late-stage melanoma trial" | Attributes the claim to the companies in the headline itself ("say"), and foregrounds that the effect size was not released. Lowest-spin framing in the set. |
| CNBC | U.S. center, business | 3 | "Cancer vaccine from Moderna, Merck shows promise in late-stage trial; both stocks soar" | "Shows promise" and "initial" data are hedged, but the stock move shares the headline with the science, which fuses a clinical result and a trading result into one event. |
| CNN | U.S. left-of-center | 3 | "Moderna and Merck say melanoma vaccine succeeded in large trial" | Careful attribution in the headline, but the body ties the result to the administration's mRNA funding cuts, framing the science as a rebuke to policy. |
| Merck | Company press release (primary source) | 4 | "Phase 3 INTerpath-001 Trial ... Met Endpoints of Recurrence-Free Survival (RFS) and Distant Metastasis-Free Survival (DMFS)" | Precise on what was met, silent on how much. No hazard ratio, no absolute difference, and overall survival noted as immature — the omission does the persuading. |
| Bloomberg | U.S. center, business | 4 | "Moderna and Merck Revive mRNA Hopes With Melanoma Success" | "Revive" frames the story as a comeback narrative for a technology under political attack — a judgment about mRNA's standing, layered on top of a single trial readout. |
| Al Jazeera | Qatari state-funded | 5 | "Moderna, Merck unveil mRNA-based cancer vaccine that cuts spread" | "Unveil" and "cuts spread" read as a finished product rather than an unpublished interim readout. The U.S. political fight over mRNA funding is absent, as is the market reaction. |
| Fox Television Stations | U.S. right-leaning ownership | 6 | "Moderna cancer vaccine cuts melanoma risk in breakthrough trial, shares surge 160%" | "Breakthrough" is asserted, not attributed, and "cuts melanoma risk" states an effect size the companies never released. The 160% figure is an intraday move, not the 176.97% close. |
References
- Merck and Moderna Announce Phase 3 INTerpath-001 Trial of Intismeran Autogene Plus KEYTRUDA Met Endpoints of Recurrence-Free Survival (RFS) and Distant Metastasis-Free Survival (DMFS) in Patients With Completely Resected Stage IIB-IV Melanoma — Merck · Company press release — one of the two sponsors of the trial
- Merck and Moderna Announce Phase 3 INTerpath-001 Trial ... Met Endpoints of RFS and DMFS in Melanoma — Moderna · Company newsroom — the other trial sponsor
- Moderna and Merck say mRNA cancer vaccine succeeded in late-stage melanoma trial — STAT · U.S. health and biotech trade outlet owned by Boston Globe Media
- Personalized cancer vaccine from Moderna, Merck shows promise in first late-stage melanoma trial — CNBC · U.S. business network owned by Comcast/NBCUniversal
- Stock Market Today, Aug. 19: Moderna Skyrockets 177% on Positive Phase 3 Melanoma Data — The Motley Fool · U.S. retail-investor publisher; sells stock subscriptions
- Moderna cancer vaccine cuts melanoma risk in breakthrough trial, shares surge 160% — Fox Television Stations · U.S. right-leaning ownership (Fox Corporation) local station group
- Moderna, Merck unveil mRNA-based cancer vaccine that cuts spread — Al Jazeera · Qatari state-funded international broadcaster
- Moderna and Merck Revive mRNA Hopes With Melanoma Success — Bloomberg · U.S. financial news, privately held by Michael Bloomberg
- Merck and Moderna say mRNA melanoma vaccine hits goals in late-stage trial — CBC News · Canadian public broadcaster, government-funded
- HHS Winds Down mRNA Vaccine Development Under BARDA — U.S. Department of Health and Human Services · U.S. federal agency statement under Secretary Robert F. Kennedy Jr.
- Moderna and Merck Present 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA in Patients With High-Risk Stage III/IV Melanoma at the 2026 ASCO Annual Meeting — Merck · Company press release — trial sponsor, Phase 2b data
- Moderna stock nearly doubles as Merck-partnered mRNA cancer vaccine meets Phase 3 goal — BioSpace · U.S. biotech industry trade publication, advertising- and recruitment-funded
- Moderna and Merck say melanoma vaccine succeeded in large trial — CNN · U.S. left-of-center cable network owned by Warner Bros. Discovery
- Moderna Shares Surge Almost Threefold on Melanoma Success, Though Stock Value Outpaces Revenue — ts2.tech · Small independent tech/finance aggregator; secondary source, figures should be treated as its own compilation
- Under Trump, mRNA Skepticism Threatens a Promising Technology — Undark · U.S. nonprofit science magazine funded by the Knight Science Journalism Program at MIT; editorially critical of the administration's vaccine policy
- RFK Jr. Axes $500 Million in Funding for mRNA Vaccine Development — The American Journal of Managed Care · U.S. peer-reviewed managed-care trade journal, industry-advertising funded